World CDx Boston 2014 has Sold Out

  With only a week to go before the meeting, World CDx Boston 2014 has sold out! There are literally no more seats available.

Featuring Speakers

  • David JacksonVice President, Diagnostics & Companion Diagnostics Arno Therapeutics

  • Kenneth EmancipatorDirector, Head of Companion Diagnostics Merck

  • Jonathan RoySenior Director, Head of Commercial Diagnostics Strategy GSK

  • Greg ZdechlikChief Operating Officer, Diagnostics Eli Lilly

Forging the Path to Precision Medicine

World CDx Boston 2014 is the 5th annual summit which will provide the springboard for your companion diagnostic strategy to reach the next level of success. By bringing together the industry’s leaders and those pushing the boundaries with companion diagnostics, World CDx Boston 2014 will be discussing and tackling the biggest opportunities and challenges in the precision medicine space.

World CDx Boston 2014 will enable you to maximize your understanding of disease heterogeneity, revolutionize validation of clinically relevant biomarkers with incorporation into clinical trial design, and master the co-development and commercialization of drug-CDx combinations.

This summit will deliver a multitude of interactive formats, such as one-on-one keynote interviews, live virtual Twitter debates, breakout roundtables, panel discussions and much more.

This dynamic platform will allow you to leverage ground-breaking advances with companion diagnostics and provide you with extensive opportunities to network with the fields leaders and those who feel confined by the same challenges as you. World CDx Boston 2014 will provide you with the blueprint to maximize your drug-companion diagnostic research.

A dedicated 3 day conference, World CDx Boston 2014 delivers pioneering case studies and discussions to ensure you learn how to:

  • Construct and develop complete biomarker strategies dealing with incorporation of biomarkers into clinical trial design, huge data sets, patient stratification and more 
  • Maximize the power of Next Generation Sequencing in the pre-clinical and clinical phases of development 
  • Amplify your drug-companion diagnostic research inside and outside of oncology to supercharge your entire portfolio
  • Navigate the regulatory and commercialization landscapes to accelerate speed to market
  • Coordinate Rx-CDx development to ensure practical alignment and ensure that launch is efficient
  • Realize the potential of cell free DNA, liquid biopsies and circulating cancer biomarkers to unearth novel approaches to drug-CDx development